policy initiatives that make India an even more attractive destination for pharmaceutical R&D and manufacturing. As an industry, we must come together to shape the future of Indian life sciences and secure our place at the forefront of global innovation”. Commenting on the potential of India’s CRDMO sector, Vikash Agarwalla, Managing Director and Partner at BCG, says, “India’s CRDMO industry is at the beginning of its “Amritkaal”, with many strong tailwinds. Our report highlights how India’s inherent strengths—small molecule expertise, cost competitiveness, and a rapidly growing innovation ecosystem—provides the springboard to becoming a dominant player in the global CRDMO market. However, unlocking this full potential will require collective push from both industry and policymakers. With the right investments in infrastructure, talent, and policy simplifications, we can truly emerge as the innovation and manufacturing hub for the global pharma industry.” Smruthi Suryaprakash, Partner at BCG, adds, “The global pharmaceutical landscape is evolving, and India has the potential to play a transformative role in shaping the future of drug discovery and advanced manufacturing. As the industry moves up the tech curve to biologics, gene therapies, and next-generation modalities, Indian CRDMOs must aggressively expand capabilities in these high-growth areas. By addressing regulatory bottlenecks, fostering cutting-edge R&D collaborations, and scaling talent development, India can emerge as a leader not just in small molecules but in next gen technologies. The time to act is now - building a world-class CRDMO ecosystem will be crucial to India’s ambition of becoming a global life sciences hub.” To unlock India’s CRDMO potential, the report highlights five key imperatives: accelerating talent development through industry-ready curricula and upskilling initiatives, streamlining policies with a CRDMO-focused regulatory framework, strengthening the supplier ecosystem by incentivizing local manufacturers and establishing Innovation Parks, expanding capital access by designating CRDMO as a sunrise sector, and enhancing sustainability through green practices and adherence to global ESG benchmarks. With strategic investments, policy interventions, and global partnerships, India’s CRDMO sector can drive economic growth, job creation, and global pharmaceutical leadership. The next decade presents an unparalleled opportunity to solidify India’s position as the world’s leading CRDMO hub. BCG-IPSO REPORT GRANT PLAYTER Editor 24/7 BIOPHARMA
RkJQdWJsaXNoZXIy MjY2OTA4MA==